Tocilizumab versus adalimumab for rheumatoid arthritis

The Lancet

Volumn 381, Issue 9877, 2013, Pages 1515-1517

  De Vita, Salvatore ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; CHOLESTEROL; METHOTREXATE; TOCILIZUMAB;

DRUG EFFICACY; DRUG SAFETY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MEDICAL SOCIETY; MONOTHERAPY; NEUTROPENIA; NOTE; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTE COUNT;

EID: 84877302334     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60634-0     Document Type: Note

References (9)

1. C Gabay, P Emery, R van Vollenhoven et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Lancet 381 2013 1541 1550
2. JS Smolen, R Landewè, FC Breedveld et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anthireumatic drugs Ann Rheum Dis 69 2010 964 975
3. JL Nam, KL Winthrop, RF van Vollenhoven et al. Current evidence for the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA Ann Rheum Dis 69 2010 976 986
4. FC Breedveld, MH Weisman, AF Kavanaugh et al. The PREMIER study: a multicentre, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 2006 26 37 (Pubitemid 43122183)
5. M Schoels, D van der Heijde, F Breedveld et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement Ann Rheum Dis 72 2013 583 589
6. M Schoels, J Wong, DL Scott et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis Ann Rheum Dis 69 2010 996 1104
7. Y Tanaka Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis Curr Opin Rheumatol 24 2012 319 326
8. R O'Mahony, A Richards, C Deighton, D Scott Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis Ann Rheum Dis 69 2010 1823 1826
9. M Fabris, L Quartuccio, E Vital et al. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumour necrosis factor blockers Arthritis Rheum 65 2013 88 97